Review
Open access
Sep 2026
Clinical and genomic characterization of KRAS G13X non-small cell lung carcinoma
KRAS G13X mutations represent a small but clinically meaningful subset of NSCLC defined by a distinctive co-mutation pattern and Combinational therapeutic strategies addressing these vulnerabilities can help improve outcomes.
Benjamin J. Staum, Rachaita Lakra, A. Ravindra et al.
· Frontiers in Oncology · 0 citations